Supplementary figure 1

Enrolled (n=17)

Allocation

**FLU cohort**
- Allocated to intervention (n=12)
- Received allocated intervention (n=12)

**LET cohort**
- Allocated to intervention (n=5)
- Received allocated intervention (n=5)

Safety cohort
- Evaluated for DLT (n=6)
- Analyzed for safety (n=12)

Efficacy cohort
- Analyzed for efficacy (n=11)
- Excluded from analysis for ineligibility (n=1)

**BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)**
**Supplementary figure 2**

---

**IL-11**

- **TWEAK/TNFSF12**

- **sCD30/TNFRSF8**

- **Pentraxin-3**

---

*** p < 0.001, ** p < 0.01, * p < 0.05
Supplementary figure 3

**PD-1/Effecter Treg(Fr.II)**

*** p < 0.001, ** p < 0.01, * p < 0.05
### Supplementary Figure 4

<table>
<thead>
<tr>
<th>Patient</th>
<th>HLA</th>
<th>ABCG2</th>
<th>F-01</th>
<th>F-02</th>
<th>F-03</th>
<th>F-04</th>
<th>F-05</th>
<th>F-06</th>
<th>F-07</th>
<th>F-08</th>
<th>F-09</th>
<th>F-10</th>
<th>F-11</th>
<th>F-12</th>
<th>L-01</th>
<th>L-02</th>
<th>L-03</th>
<th>L-04</th>
<th>L-05</th>
<th>L-06</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>01</td>
<td>02</td>
<td>03</td>
<td>04</td>
<td>05</td>
<td>06</td>
<td>07</td>
<td>08</td>
<td>09</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Peak value shown in Table 4*